vs
Side-by-side financial comparison of BCB BANCORP INC (BCBP) and CytomX Therapeutics, Inc. (CTMX). Click either name above to swap in a different company.
BCB BANCORP INC is the larger business by last-quarter revenue ($26.2M vs $18.7M, roughly 1.4× CytomX Therapeutics, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -49.7%, a 48.8% gap on every dollar of revenue. On growth, BCB BANCORP INC posted the faster year-over-year revenue change (13.1% vs -25.7%). BCB BANCORP INC produced more free cash flow last quarter ($34.9M vs $-15.8M). Over the past eight quarters, BCB BANCORP INC's revenue compounded faster (1.8% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
BCBP vs CTMX — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $26.2M | $18.7M |
| Net Profit | $-12.0M | $-154.0K |
| Gross Margin | — | — |
| Operating Margin | -71.9% | -6.9% |
| Net Margin | -49.7% | -0.8% |
| Revenue YoY | 13.1% | -25.7% |
| Net Profit YoY | -467.6% | 97.6% |
| EPS (diluted) | $-0.73 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $26.2M | — | ||
| Q3 25 | $26.5M | — | ||
| Q2 25 | $25.2M | $18.7M | ||
| Q1 25 | $23.8M | $50.9M | ||
| Q4 24 | $23.1M | $38.1M | ||
| Q3 24 | $26.2M | $33.4M | ||
| Q2 24 | $20.4M | $25.1M | ||
| Q1 24 | $25.3M | $41.5M |
| Q4 25 | $-12.0M | — | ||
| Q3 25 | $4.3M | — | ||
| Q2 25 | $3.6M | $-154.0K | ||
| Q1 25 | $-8.3M | $23.5M | ||
| Q4 24 | $3.3M | $18.9M | ||
| Q3 24 | $6.7M | $5.7M | ||
| Q2 24 | $2.8M | $-6.5M | ||
| Q1 24 | $5.9M | $13.8M |
| Q4 25 | -71.9% | — | ||
| Q3 25 | 21.9% | — | ||
| Q2 25 | 19.9% | -6.9% | ||
| Q1 25 | -49.2% | 44.4% | ||
| Q4 24 | 19.9% | 46.4% | ||
| Q3 24 | 35.7% | 12.3% | ||
| Q2 24 | 19.5% | -33.7% | ||
| Q1 24 | 33.0% | 28.1% |
| Q4 25 | -49.7% | — | ||
| Q3 25 | 16.1% | — | ||
| Q2 25 | 14.2% | -0.8% | ||
| Q1 25 | -35.0% | 46.2% | ||
| Q4 24 | 14.1% | 49.6% | ||
| Q3 24 | 25.5% | 17.2% | ||
| Q2 24 | 13.8% | -26.0% | ||
| Q1 24 | 23.2% | 33.3% |
| Q4 25 | $-0.73 | — | ||
| Q3 25 | $0.22 | — | ||
| Q2 25 | $0.18 | — | ||
| Q1 25 | $-0.51 | — | ||
| Q4 24 | $0.17 | — | ||
| Q3 24 | $0.36 | — | ||
| Q2 24 | $0.14 | — | ||
| Q1 24 | $0.32 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $49.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $304.3M | $119.9M |
| Total Assets | $3.3B | $175.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $49.0M | ||
| Q1 25 | — | $47.6M | ||
| Q4 24 | — | $38.1M | ||
| Q3 24 | — | $40.6M | ||
| Q2 24 | — | $43.2M | ||
| Q1 24 | — | $36.2M |
| Q4 25 | $304.3M | — | ||
| Q3 25 | $318.5M | — | ||
| Q2 25 | $315.7M | $119.9M | ||
| Q1 25 | $314.7M | $25.0M | ||
| Q4 24 | $323.9M | $-456.0K | ||
| Q3 24 | $328.1M | $-23.5M | ||
| Q2 24 | $320.7M | $-31.2M | ||
| Q1 24 | $320.1M | $-31.7M |
| Q4 25 | $3.3B | — | ||
| Q3 25 | $3.4B | — | ||
| Q2 25 | $3.4B | $175.1M | ||
| Q1 25 | $3.5B | $98.5M | ||
| Q4 24 | $3.6B | $120.5M | ||
| Q3 24 | $3.6B | $139.0M | ||
| Q2 24 | $3.8B | $159.2M | ||
| Q1 24 | $3.8B | $184.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.9M | $-15.8M |
| Free Cash FlowOCF − Capex | $34.9M | $-15.8M |
| FCF MarginFCF / Revenue | 133.3% | -84.6% |
| Capex IntensityCapex / Revenue | 4.0% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $58.2M | $-77.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.9M | — | ||
| Q3 25 | $8.7M | — | ||
| Q2 25 | $10.3M | $-15.8M | ||
| Q1 25 | $5.0M | $-21.0M | ||
| Q4 24 | $67.7M | $-19.9M | ||
| Q3 24 | $43.5M | $-20.7M | ||
| Q2 24 | $8.1M | $-19.5M | ||
| Q1 24 | $8.3M | $-26.0M |
| Q4 25 | $34.9M | — | ||
| Q3 25 | $8.5M | — | ||
| Q2 25 | $10.2M | $-15.8M | ||
| Q1 25 | $4.7M | $-21.2M | ||
| Q4 24 | $66.5M | $-20.0M | ||
| Q3 24 | $43.4M | $-20.7M | ||
| Q2 24 | $8.1M | $-19.6M | ||
| Q1 24 | $8.1M | $-26.2M |
| Q4 25 | 133.3% | — | ||
| Q3 25 | 32.0% | — | ||
| Q2 25 | 40.4% | -84.6% | ||
| Q1 25 | 19.8% | -41.6% | ||
| Q4 24 | 287.5% | -52.5% | ||
| Q3 24 | 166.0% | -62.1% | ||
| Q2 24 | 39.6% | -78.2% | ||
| Q1 24 | 32.3% | -63.1% |
| Q4 25 | 4.0% | — | ||
| Q3 25 | 1.1% | — | ||
| Q2 25 | 0.6% | 0.1% | ||
| Q1 25 | 1.2% | 0.2% | ||
| Q4 24 | 5.3% | 0.2% | ||
| Q3 24 | 0.3% | 0.1% | ||
| Q2 24 | 0.2% | 0.4% | ||
| Q1 24 | 0.6% | 0.3% |
| Q4 25 | — | — | ||
| Q3 25 | 2.05× | — | ||
| Q2 25 | 2.90× | — | ||
| Q1 25 | — | -0.89× | ||
| Q4 24 | 20.70× | -1.05× | ||
| Q3 24 | 6.53× | -3.61× | ||
| Q2 24 | 2.88× | — | ||
| Q1 24 | 1.41× | -1.89× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCBP
Segment breakdown not available.
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
